Moreover, the therapeutic potential of modulating inflammasome pathways has gained traction, with several studies exploring NLRP3 inhibitors or IL-1β blockade in preclinical models of psoriasis and other chronic inflammatory diseases (Tsuji et al., 2020). This evidence concerns the gene IL1B and psoriasis.